If youve been doing the right things and still feel stuck, its normal to look for support that doesnt feel extreme
Understanding peptide safety and risks is essential context for evaluating any peptide with limited human trial data
Splice switching oligonucleotides (SSO) act by binding to pre-mRNA and modulating splicing to effectuate the generation of different isoforms
59% Increase in total sleep time vs placebo (controlled study) 37 mo Normal sleep maintained after the last dose (chronic insomniacs) 1977 Year DSIP was first isolated 0 Documented dependence or withdrawal in clinical studies Studies show increased delta wave sleep Research on cortisol normalization Trials in chronic pain patients Demonstrated stress-reducing effects What to expect Your DSIP timeline
Key Improvements REI helped redesign the portal into a cloud-based framework with an intuitive user interface and microservices architecture, which simplifies the application process, making it easier for 16 DoD components to find and support innovative ideas more efficiently
The conditions that most commonly support eligibility include: Obesity (BMI 30, or 27 with at least one comorbidity such as hypertension, sleep apnea, or cardiovascular disease) Type 2 diabetes or prediabetes Insulin resistance with clinical documentation Metabolic syndrome (clinically diagnosed) Polycystic Metabolic Ovarian Syndrome (PMOS) and related hormonal disorders Non-alcoholic fatty liver disease (NAFLD/MASLD) Perimenopause-related metabolic dysfunction with documented hormonal changes GLP-1 receptor agonists including semaglutide, tirzepatide, and retatrutide are the most commonly used peptides in metabolic care today
